| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)NCT05125068 | Eledon Pharmaceuticals | Phase 2 | Terminated | 2023-07-31Actual |
| Setrusumab vs Placebo for Osteogenesis ImperfectaNCT05125809 | RARE | Phase 2, Phase 3 | Active not recruiting | 2025-10-20Actual |
| Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsNCT05126433 | Jazz Pharmaceuticals | Phase 2 | Terminated | 2023-12-20Actual |
| HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromeNCT05127226 | IONS | Phase 1, Phase 2 | Active not recruiting | 2032-03Estimated |
| A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAHNCT05128942 | Spruce Biosciences | Phase 2 | Terminated | 2025-01-31Actual |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)NCT05130450 | IONS | Phase 3 | Active not recruiting | 2028-02Estimated |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasNCT05130866 | RXRX | Phase 2, Phase 3 | Terminated | 2025-08-18Actual |
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441 | Immunic AG | Phase 3 | Active not recruiting | 2026-11Estimated |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)NCT05136898 | URGN | Phase 3 | Completed | 2023-02-02Actual |
| A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)NCT05139316 | RARE | Phase 3 | Completed | 2024-02-20Actual |
| OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)NCT05139810 | IONS | Phase 3 | Completed | 2023-11-09Actual |
| A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia VeraNCT05143957 | IONS | Phase 2 | Completed | 2025-06-26Actual |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodNCT05144256 | AGIO | Phase 3 | Active not recruiting | 2024-05-03Actual |
| A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT05147233 | Oculis | Phase 3 | Completed | 2023-06-22Actual |
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLNCT05147467 | Ascentage Pharma Group Inc. | Phase 2 | Recruiting | 2026-12Estimated |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147 | Jazz Pharmaceuticals | Phase 3 | Active not recruiting | 2026-07-15Actual |
| A Study of Oral ARD-101 in Patients With Prader-Willi SyndromeNCT05153434 | AARD | Phase 2 | Completed | 2024-09-24Actual |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)NCT05155254 | IO Biotech | Phase 3 | Active not recruiting | 2025-05-30Actual |
| Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamNCT05156320 | Scholar Rock, Inc. | Phase 3 | Completed | 2024-12-18Actual |
| ALTO-300 in Depression (ALTO-300-004)NCT05157945 | Alto Neuroscience | Phase 2 | Completed | 2023-04-26Actual |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)NCT05162066 | BioCryst Pharmaceuticals | Phase 2 | Terminated | 2022-09-23Actual |
| A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaNCT05166161 | PTC Therapeutics | Phase 3 | Completed | 2026-07-21Actual |
| A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMNCT05174416 | LianBio LLC | Phase 3 | Completed | 2023-03-06Actual |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodNCT05175105 | AGIO | Phase 3 | Active not recruiting | 2024-12-13Actual |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate CancerNCT05177770 | CHRS | Phase 2 | Terminated | 2023-04-05Actual |
| Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT05177835 | ABVX | Phase 2 | Active not recruiting | 2028-03Estimated |
| A Study of JZP150 in Adults With Posttraumatic Stress DisorderNCT05178316 | Jazz Pharmaceuticals | Phase 2 | Completed | 2023-12-05Actual |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleNCT05178862 | SCYX | Phase 3 | Terminated | 2025-11-07Actual |
| Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisNCT05180240 | CRDL | Phase 2 | Completed | 2025-01-31Actual |
| A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia CongenitaNCT05180708 | PVLA | Phase 3 | Completed | 2023-06-30Actual |
Trial details
- Registry ID
- NCT05125068
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05125809
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05126433
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05127226
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT05128942
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05130450
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05130866
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05134441
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05136898
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05139316
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05139810
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05143957
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05144256
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05147233
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05147467
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05152147
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05153434
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05155254
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05156320
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05157945
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05162066
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05166161
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05174416
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05175105
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05177770
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05177835
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05178316
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05178862
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05180240
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05180708
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.